Treatment to reduce inflammation and improve immune recovery among older HIV pts

减少老年艾滋病患者炎症并改善免疫恢复的治疗

基本信息

  • 批准号:
    9038208
  • 负责人:
  • 金额:
    $ 55.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-04-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: Treated HIV positive patients are at increased risk for cardiovascular disease (CVD), cancer, and other HIV- associated non-AIDS conditions. Ongoing immune activation, despite effective treatment with antiretroviral therapy (ART), increases risk for CVD and non-AIDS conditions, but also contributes to lymphatic tissue fibrosis, limiting immune recovery that further increases risk for non-AIDS conditions. Biologic aging also leads to systemic inflammation and waning immune function, and, thus, non-AIDS conditions and poly-morbidity will continue to increase as the HIV population ages. Identifying safe treatments that target this pathology represents a major unmet need for older HIV positive patients. We propose a randomized placebo-controlled trial of losartan (100mg daily) among n=120 antiretroviral-treated HIV positive persons age >50 years receiving effective ART with undetectable HIV RNA levels. We will study the treatment effects of losartan on changes in IL-6 levels over 6 months and changes in peripheral blood CD4 count over 12 months. We hypothesize that losartan treatment will: a) reduce systemic inflammation that will be accounted for through reductions in monocyte activation within peripheral blood, and b) lead to immune recovery, as reflected in blood CD4+ count, via down-regulating immune activation and TGF-β-mediated fibrosis in lymphatic tissues that will improve T- cell homeostasis and survival of naive T-cells. Our investigative team has helped define the role of inflammation in non-AIDS disease risk as well as developed the model that links lymph node fibrosis with impaired T-cell homeostasis. This work directly informed our choice of outcomes, which both test fundamental HIV pathogenesis questions and will determine if losartan improves immune activation and immune recovery to a degree that may be clinically relevant. Our methods and hypotheses are innovative, our intervention is novel in the context of HIV infection, and our approach provides essential randomized data to inform and justify the expense of subsequent clinical outcome trials. In summary, this translational trial addresses a high priority HIV research agenda to identify disease-modifying strategies for non-AIDS conditions among older patients.
描述:接受治疗的 HIV 阳性患者患心血管疾病 (CVD)、癌症和其他与 HIV 相关的非艾滋病疾病的风险增加。尽管抗逆转录病毒疗法 (ART) 有效,但持续的免疫激活会增加 CVD 和非艾滋病疾病的风险,而且还会导致淋巴组织纤维化,限制免疫恢复,从而进一步增加非艾滋病疾病的风险。生物衰老还会导致全身炎症和免疫功能减弱,因此,随着艾滋病毒人口老龄化,非艾滋病疾病和多发病率将继续增加。确定针对这种病理学的安全治疗方法是老年艾滋病毒阳性患者未满足的主要需求。我们建议对 120 名年龄 > 50 岁、接受有效 ART 且 HIV RNA 水平未检测到的接受过抗逆转录病毒治疗的 HIV 阳性患者进行氯沙坦(每天 100 毫克)的随机安慰剂对照试验。我们将研究氯沙坦对 6 个月内 IL-6 水平变化和 12 个月内外周血 CD4 计数变化的治疗效果。我们假设氯沙坦治疗将:a)通过减少外周血中的单核细胞活化来减少全身炎症,b)通过下调淋巴组织中的免疫活化和TGF-β介导的纤维化来改善T细胞稳态和初始T细胞的存活,从而导致免疫恢复,如血​​液CD4+计数所反映。我们的研究团队帮助确定了炎症在非艾滋病疾病风险中的作用,并开发了将淋巴结纤维化与 T 细胞稳态受损联系起来的模型。这项工作直接影响了我们对结果的选择,这些结果既测试了基本的艾滋病毒发病机制问题,也将确定氯沙坦是否可以将免疫激活和免疫恢复改善到可能与临床相关的程度。我们的方法和假设是创新的,我们的干预措施在艾滋病毒感染的背景下是新颖的,我们的方法提供了必要的随机数据来告知和证明后续临床结果试验的费用是合理的。总之,这项转化试验解决了一个高度优先的艾滋病毒研究议程,以确定老年患者非艾滋病状况的疾病缓解策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jason V Baker其他文献

Jason V Baker的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jason V Baker', 18)}}的其他基金

Immunologic basis of cardiac disease after severe COVID-19
重症COVID-19后心脏病的免疫学基础
  • 批准号:
    10442251
  • 财政年份:
    2022
  • 资助金额:
    $ 55.9万
  • 项目类别:
Immunologic basis of cardiac disease after severe COVID-19
重症COVID-19后心脏病的免疫学基础
  • 批准号:
    10650182
  • 财政年份:
    2022
  • 资助金额:
    $ 55.9万
  • 项目类别:
Optimization of a behavioral intervention to increase physical activity in older adults living with HIV
优化行为干预以增加艾滋病毒感染者老年人的体力活动
  • 批准号:
    10693938
  • 财政年份:
    2022
  • 资助金额:
    $ 55.9万
  • 项目类别:
Optimization of a behavioral intervention to increase physical activity in older adults living with HIV
优化行为干预以增加艾滋病毒感染者老年人的体力活动
  • 批准号:
    10481551
  • 财政年份:
    2022
  • 资助金额:
    $ 55.9万
  • 项目类别:
Clinical and immunologic factors underlying heart failure with preserved ejection fraction among persons with HIV in South Africa
南非艾滋病毒感染者射血分数保留的心力衰竭的临床和免疫因素
  • 批准号:
    10325041
  • 财政年份:
    2021
  • 资助金额:
    $ 55.9万
  • 项目类别:
Clinical and immunologic factors underlying heart failure with preserved ejection fraction among persons with HIV in South Africa
南非艾滋病毒感染者射血分数保留的心力衰竭的临床和免疫因素
  • 批准号:
    10685376
  • 财政年份:
    2021
  • 资助金额:
    $ 55.9万
  • 项目类别:
PrEP iT! A Pilot Test of a Mobile Peer Support Intervention to Optimize PrEP Adherence and Retention in PrEP Care
PrEP iT!
  • 批准号:
    10116478
  • 财政年份:
    2019
  • 资助金额:
    $ 55.9万
  • 项目类别:
Treatment to reduce inflammation and improve immune recovery among older HIV pts
减少老年艾滋病患者炎症并改善免疫恢复的治疗
  • 批准号:
    8641495
  • 财政年份:
    2014
  • 资助金额:
    $ 55.9万
  • 项目类别:
Treatment to reduce inflammation and improve immune recovery among older HIV pts
减少老年艾滋病患者炎症并改善免疫恢复的治疗
  • 批准号:
    8883185
  • 财政年份:
    2014
  • 资助金额:
    $ 55.9万
  • 项目类别:
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease
靶向抗凝治疗可减少治疗艾滋病毒疾病中的炎症
  • 批准号:
    8846913
  • 财政年份:
    2014
  • 资助金额:
    $ 55.9万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 55.9万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 55.9万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 55.9万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 55.9万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 55.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 55.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 55.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 55.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 55.9万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 55.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了